Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;76(7):2226-2229.
doi: 10.1111/all.14721. Epub 2021 Jan 12.

Chemical modification of ragweed extract results in an increased safety profile while maintaining immunogenicity

Sara Huber  1 , Hanneke van der Kleij  2 , Sabrina Wildner  1 , Martin Wolf  1 , Michael Wallner  1 , Heidi Hofer  1 , Claudia Asam  1 , Peter Briza  1 , Fatima Ferreira  1 , Michael Hauser  1
Affiliations

Chemical modification of ragweed extract results in an increased safety profile while maintaining immunogenicity

Sara Huber et al. Allergy. 2021 Jul.
No abstract available

Keywords: allergoid; immunogenicity; pollen extract; ragweed immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Hanneke P.M van der Kleij is an employee of HAL Allergy. Fatima Ferreira is a member of Scientific Advisory Boards (HAL Allergy, NL; SIAF, Davos, CH; AllergenOnline, USA) and has been supported by the Austrian Science Funds (FWF). Martin Wolf, Michael Hauser, Sara Huber, Sabrina Wildner, Claudia Asam, Heidi Hofer, Peter Briza, and Michael Wallner have no conflict of interest to declare.

Figures

FIGURE 1
FIGURE 1
Mediator release assay (huRBL). A, Mediator release assay (huRBL). Antigen concentration needed to reach 25% ß‐hexosaminidase release is 500‐fold higher in MRE compared with RE (patients 14 and 15 were excluded from analysis since stimulation with MRE did not reach the 25% of the ß‐hexosaminidase release). B, IgE‐binding capacities of RE and MRE were analyzed by indirect ELISA (n = 15). C) IgE cross‐reactivity between RE and MRE was addressed by inhibition ELISA experiments (n = 15). Statistics were calculated by the Mann‐Whitney test and unpaired t test. **p < 0.01 and ***p < 0.001
FIGURE 2
FIGURE 2
Mouse IgG ELISA and mediator release assay (muRBL). IgG against coated RE (A) and coated natural purified Amb a 1 (B) were determined by ELISA. Female BALB/c mice (n = 10 per group) were s.c. injected with 10 µg MRE or with its equivalent RE both adsorbed to Al(OH)3 per mouse on days 0, 7, 14, and 21. Control mice (n = 6) were injected with PBS (with alum) only. Specific IgG titers were determined in single serum samples obtained at days −1 (pre‐sera), 13 (2nd immunization), and 28 (4th immunization). C, Mediator release of RBL cells passively sensitized with murine sera obtained at day 28 and stimulated with 100 ng/ml RE. Data represent ß‐hexosaminidase release of cells after subtraction of background (0% release) relative to 100% release values observed with 10% Triton X‐100. Statistics were calculated by the Kruskal‐Wallis followed by Dunn's post‐test, respectively. *p < 0.05, **p < 0.01, and ***p < 0.001
See this image and copyright information in PMC

References

    1. Burbach GJ, Heinzerling LM, Röhnelt C, Bergmann KC, Behrendt H, Zuberbier T. GA(2)LEN study. Ragweed sensitization in Europe ‐ GA(2)LEN study suggests increasing prevalence. Allergy. 2009;64(4):664‐665. - PubMed
    1. Salo PM, Calatroni A, Gergen PJ, et al. Allergy‐related outcomes in relation to serum IgE: results from the national health and nutrition examination survey 2005–2006. J Allergy Clin Immunol. 2011;127(5):1226. - PMC - PubMed
    1. Wolf M, Twaroch TE, Huber S, et al. Amb a 1 isoforms: unequal siblings with distinct immunological features. Allergy. 2017;72(12):1874‐1882. - PMC - PubMed
    1. Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J Allergy Clin Immunol Pract. 2014;2(2):144‐149. - PubMed
    1. Himly M, Carnes J, Fernandez‐Caldas E, Briza P, Ferreira F. Characterization of allergoids. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess. 2009;96:61‐69;discussion 69–70. - PubMed

Publication types